Efficacy in focal epilepsy
How efficacious is Keppra as monotherapy?
Anoro Ellipta 20 mcg
has been lorem added to your basket
Keppra significantly reduced the percentage of seizure days/week vs placebo in patients with adolescent-onset generalised epilepsy as an adjunct1
Median percentage reduction from baseline in seizure days/week over the treatment period (up-titration and maintenance)1
Supplementary analysis of two double-blind, placebo-controlled trials. Patients received LEV (target dose: adults 3000 mg/day; children 60 mg/kg/day) or placebo for 16–24 weeks (including 4-week up-titration) in addition to 1–2 anti-epileptic drugs. Patients across the two studies were aged 4–65 years.1
The same results were first published in Rosenfeld WE, et al. Epilepsy Research 2009;85:72–80. The graph has been independently created by GSK from the original data.
LEV: levetiracetam; SD: study design.
GSK shall not be liable for any damages, claims, liabilities, costs or obligations arising from the use or misuse of information provided herein.
For safety information on GSK products or to report an Adverse Event, please contact the toll free line
0800 CALL GSK (0800 2255 475) or email firstname.lastname@example.org
Full prescribing information is available on request on www.gskpro.com
Please note that it may take up to 10 days to process your request. If you need further assistance contact
GSK House, 1 Industrial Avenue llupeju, Lagos or via email at email@example.com
GlaxoSmithKline Pharmaceutical Nigeria Ltd, 1 Industrial Avenue, llupeju, Lagos 234-1-271 1000
©2020 GSK group of companies or its licensor
Trade marks are owned by or licensed to the GSK group of companies
Keppra is a registered trademark of the GlaxoSmithKline group of companies
PM-NG-LVT-WCNT-200004 Date of preparation: November 2020.